The study is funded by a $2.87 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases.
By A.J. Hostetler
Researchers at the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University hope a new five-year study will help them develop better diagnostic tools for patients with an aggressive liver disease that is a leading cause for liver transplantation.
In patients suffering from metabolic dysfunction-associated steatotic liver disease (MASH, formerly called NASH), a build-up of fat in the liver damages cells and causes inflammation.
Read the full article in the VCUHealth News Center.